Quantcast
Last updated on April 23, 2014 at 12:16 EDT
Studies Investigate New Less Toxic Treatments For Hepatitis

Studies Investigate New, Less Toxic Treatments For Hepatitis C

redOrbit Staff & Wire Reports - Your Universe Online A new orally-administered antiviral therapy has reportedly cured hepatitis C infection in over 90 percent of patients with liver cirrhosis, according to research published Saturday in the...

Latest Hepatocellular carcinoma Stories

2014-04-17 15:40:57

Deaths from viral Hepatitis B and C have surpassed HIV/AIDS in many countries, including Australia and in Western Europe, according to an analysis of the 2010 Global Burden of Disease study. The analysis was conducted by Dr Benjamin Cowie and Ms Jennifer MacLachlan from the University of Melbourne and Melbourne Health, and was presented at The International Liver Congress in London earlier this month. “Liver cancer is the fastest increasing cause of cancer deaths in Australia,...

2014-04-15 23:10:44

A new study published in The Oncologist journal shows that a subset of patients with advanced differentiated thyroid cancer (DTC) and multiple comorbidities in which full-dose sorafenib is considered unsafe can initiate treatment with sorafenib at lower starting doses without adversely affecting efficacy or tolerability compared with full-dose sorafenib. A team of researchers led by Ramona Dadu, MD, at the MD Anderson Cancer Center in Houston, TX, performed a retrospective analysis to...

2014-04-14 12:33:05

CALGARY, April 14, 2014 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC) (NASDAQ:ONCY) today announced that Dr. Adel Jebar of the Leeds Institute of Cancer and Pathology, University of Leeds, presented a poster at the 8(th) Annual International Conference on Oncolytic Virus Therapeutics held in Oxford, UK. The poster, titled "Combined anti-viral and anti-tumour therapy for virus-associated liver cancer," covered preclinical research into the treatment of hepatocellular...

2014-04-14 12:33:30

Epidemiological, genetic and clinical data presented today at the International Liver CongressTM 2014 are collectively focused on different approaches designed to improve the diagnosis, staging and treatment of hepatocellular carcinoma (HCC). "Human hepatocellular carcinoma is one of the most prevalent cancers worldwide and the second most frequent cause of cancer-related death," said EASL's Scientific Committee Member Dr Helen Reeves Senior Lecturer & Honorary Consultant...

2014-04-11 13:01:17

Significant new data presented today at the International Liver Congress™ 2014 indicate that liver cancer (Hepatocellular Carcinoma (HCC)) may be treated by adoptive T-cell therapy. This new therapeutic approach in the treatment of HCC could be very important as without treatment the 5 year survival rate is just 5%. Globally, HCC accounts for 746,000 deaths, and in the UK alone is responsible for over 4,000 deaths per year. Glypican-3 (GPC3) is a tumor associated antigen expressed in...

2014-04-10 12:28:09

Guerbet LLC, USA PRINCETON, N.J., April 10, 2014 /PRNewswire/ -- Guerbet, a pioneer in the field of contrast agents for medical imaging announced that Lipiodol® was approved by the US Food and Drug Administration pursuant to section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act indicated for selective hepatic intra-arterial use for imaging tumors in adults with known hepatocellular carcinoma (HCC). HCC is the most common primary liver tumor and represents the third-leading...

2014-04-10 08:30:03

Professor Riccardo Lencioni is giving an honorary lecture on April 24, 2014 which will highlight the latest findings and lessons learned from the HEAT Study and the design of the Phase III OPTIMA Study LAWRENCEVILLE, N.J., April 10, 2014 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN) announced today that Professor Riccardo Lencioni, MD, FSIR, EBIR, Professor and Director of the Diagnostic Imaging and Intervention at the Pisa University School of Medicine in Italy, former ECIO President,...

2014-04-10 08:29:18

--BioCrossroads Joins Twilight Ventures, Luson Bioventures and Other Investors-- INDIANAPOLIS, BLOOMINGTON, Ind. and SAN FRANCISCO, April 10, 2014 /PRNewswire/ -- Assembly Pharmaceuticals and BioCrossroads today announced that the BioCrossroads Indiana Seed Fund II has made an investment in Assembly Pharmaceuticals. Assembly is developing novel drugs for the treatment and potential cure of chronic hepatitis B virus (HBV) infection. Johnson & Johnson Development Corporation,...

2014-04-09 08:28:57

Data Supports Development as Non-Invasive Treatment Regimen in a Variety of Cancer Indications LAWRENCEVILLE, N.J., April 9, 2014 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN) announced today that data supporting the development of ThermoDox®, its proprietary heat-activated liposomal encapsulation of doxorubicin, plus high intensity focused ultrasound (HIFU) were presented on April 5, 2014 at the 14th International Symposium on Therapeutic Ultrasound in Las Vegas, Nevada. In a...

2014-04-07 12:50:07

A University of Colorado Cancer Center study published today in Journal of the National Cancer Institute (with related research being presented this weekend at the American Association for Cancer Research Annual Conference 2014) details the discovery of a new genetic driver of bladder cancer: silencing of the gene AGL. "We tend to think of cancer resulting from mutations that let genes make things they shouldn't or turn on when they should be quiet. But cancer can also result from loss of...


Latest Hepatocellular carcinoma Reference Libraries

Hepatitis B
2013-02-25 09:11:23

Image Caption: This electron micrograph reveals the presence of hepatitis-B virus HBV "Dane particles", or virions. Credit: CDC/Wikipedia Hepatitis B: What Is It? Hepatitis simply means a swelling or inflammation of the liver. The type hepatitis that a person contracts (there are 5 common forms) affects their long-term prognosis. The most common and most severe of these different types of liver infection is Hepatitis B, which is caused by the hepatitis B virus (HBV). It is typically...

45_36624a455e3cd9a4152b7670308f0ffa
2011-01-20 19:14:56

Hepatitis B virus, HBV, is a part of the Hepadnaviridae family of viruses. HBV can lead to cirrhosis and hepatocellular carcinoma and has been linked to pancreatic cancer. It is classified as a species of the Orthohepadnavirus. Similar viruses have been found worldwide in great apes and monkeys. There a few different genotypes and they all differ by at least 8% of the sequence and have distinct geographical distributions and this has been associated with anthropological history. Type A is...

0_9255b919f71eff1fd4202c1dbb1795d2
2011-01-12 15:49:29

Hepadnaviruses can cause liver infections in humans and animals. The two recognized genera are Genus Orthohepadnavirus and Genus Avihepadnavirus. It has a small genome of partially double-stranded, partially single stranded circular DNA. It is a group 7 virus that uses an RNA intermediate during replication. Most people who come into contact with the virus are able to clear the infection alone although some cannot and usually progress to fulminant hepatitis. It can cause sever liver...

More Articles (3 articles) »